Life Biosciences

Attending @FTLive’s US Pharma & Biotech Summit? Join us as our CEO, Jerry McLaughlin highlights our epigenetic restoration approach aimed at extending healthspan by reversing age-related diseases. More here: uspharma.live.ft.com/agenda/speaker… #FTPharma

Today, #ASGCT2026 kicks off and we are excited to have our team on-site to share updates from our preclinical programs of ER-100 & ER-300 in eye and liver disease & about our Phase 1 clinical trial of ER-100 in glaucoma and NAION. View our abstracts here: bit.ly/4tUTVXn

Tomorrow at #ARVO2026, our SVP, Research & Development, Lisa Stanek, PhD, will be presenting a poster detailing the preclinical profile of ER-100 at 1:15-3:00 PM during session number 346. Stop by if you’re attending to learn more!

Proud to be featured in @TIME TIME100 Companies: New Frontiers, recognizing our work to reverse age-related diseases by targeting the biology of aging. We’re honored by this recognition & remain committed to advancing transformative therapies. Read more: bit.ly/3QMUFiy

Our team is engaging across key conversations on healthspan & our approach to reverse age-related disease this April, including the Ascension Summit, Pharma Partnering Summit, @Stmlforum, and @LibertySciCtr Fireside Chat. Reach out to connect: lifebiosciences.com/contact/

90% of deaths are age-related. So why do we treat diseases one by one? What if we target aging itself? New episode with Raghav Sehgal (@rv_sehgal )& Macsue Jacques (@MacsueJ ) ft. Dr. Michael Ringel (@M_S_Ringel ) @lifebiosciences 🎧 Listen: Spotify: open.spotify.com/show/38rB6VfYG…

Q1 kicked off with strong momentum as our leadership team engaged across key industry forums, sharing perspectives on our Partial Epigenetic Reprogramming platform aimed at reversing age-related disease. Stay up to date on our progress: lifebiosciences.com

#ICYMI: Honored to be on @Nasdaq’s Tower celebrating our fully subscribed $80M Series D financing supporting our Phase 1 clinical trial & Partial Epigenetic Reprogramming platform. Thank you to our co-founders, Dr. @DavidASinclair, AO & Tristan Edwards. bit.ly/3PUqVA1

We’ve closed a fully-subscribed $80 million financing to support our ongoing clinical trial in optic neuropathies and advancement of our Partial Epigenetic Reprogramming platform across multiple indications. Read more: bit.ly/3PUqVA1

Our COO, @M_S_Ringel, JD, PhD, joined @teleodaniel & @EricDai_BioE on @FreeRadialsBio’s Podcast to discuss the biology of aging & how we are using partial epigenetic reprogramming to target the root of age-related disease, like NAION & glaucoma. Tune in: bit.ly/4tapWdl

Heading to #NANOS2026? Join us in Boston to hear a presentation on Life Bio’s partial epigenetic reprogramming platform and the preclinical profile of ER-100 in a nonhuman primate model of NAION. Learn more: bit.ly/4rDK4Dg @NANOSTweets

#ICYMI, our CSO, Sharon Rosenzweig-Lipson, PhD, was featured in @Labiotech_eu discussing how our recent IND clearance allows us to advance our lead partial epigenetic reprogramming therapy into the clinic to address optic neuropathies. Read more: bit.ly/4lvWFHj

Our CSO, Sharon Rosenzweig-Lipson, PhD, was featured in @LifespanRI sharing insights on our OSK-based partial epigenetic reprogramming platform & our upcoming Phase 1 trial aimed at establishing safety & tolerability for optic neuropathies. Read here: bit.ly/46BV1Oc

Attending @IAmBiotech’s Investment & Growth Summit? Our CEO, Jerry McLaughlin, will present on our company progress as we enter the clinic & the aim of our partial epigenetic reprogramming platform to reverse age-related diseases such as glaucoma & NAION: bit.ly/40tXZ3G

Check out @FortuneMagazine’s piece as our co-founder, Dr. @DavidASinclair, AO, & CEO, Jerry McLaughlin, discuss @FDA IND clearance of our partial epigenetic reprogramming therapy designed to reverse age-related diseases like glaucoma & NAION: bit.ly/46hpErR

#ICYMI: @LongevityTech featured our leadership team to discuss @FDA’s IND clearance of our partial epigenetic reprogramming therapy. This explores how targeting the root drivers of aging could help restore vision loss for diseases like glaucoma & NAION: bit.ly/4rns0gY

In @Endpts, our co-founder, Dr. @DavidaSinclair, CEO, Jerry McLaughlin, & CSO, Dr. Sharon Rosenzweig-Lipson, discuss our FDA-cleared IND for ER-100, our cellular rejuvenation therapy, the first step to restoring & preventing age-related vision loss: bit.ly/49W98yE

We’re pleased to announce we’ve received @FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release: bit.ly/45BKD8D

This #GlaucomaAwarenessMonth, our CSO Sharon Rosenzweig-Lipson, PhD, will speak at the Glaucoma 360 New Horizons Forum to discuss how our partial epigenetic reprogramming platform aims to target glaucoma to restore vision & extend healthspan. More here: bit.ly/4pVKrrZ

Our CEO, Jerry McLaughlin & COO, Michael Ringel will be at #JPM2026 meeting with industry leaders to discuss our platform & progress to the clinic. Michael will join @Mubadala's Networking event & moderate @WuXi_AppTec’s Forum's panel. Reach out to connect:bit.ly/3Z6qT9m